Sign in
Not yet taking people in BelgiumPhase 1

Safety of AGMB-101 in healthy people and people with liver cirrhosis

Tests how safe AGMB-101 is in healthy volunteers and people with liver cirrhosis.

Key facts

Who runs it
AgomAb Therapeutics
Where
Edegem, BelgiumSee the site
Registry title
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).
Status
Not yet recruiting
Phase
Phase 1
People taking part
64 people, planned
Started
3 Mar 2025
Planned end
7 Jan 2026
Type of study
Interventional
Record updated
27 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults (Part A) and adults with liver cirrhosis, which is scarring of the liver (Part B). It tests single, rising doses of AGMB-101.

Age
18 years and older
Sex
All sexes
Disease stage
Part B: people with liver cirrhosis. Part A: healthy people.

Where in Belgium

  • SGS BelgiumEdegem, BelgiumNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Safety of AGMB-101 in healthy people and people with liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 February 2025